Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

• Published in: Current oncology (Toronto) Vol. 29; no. 8; pp. 5955 - 5962
• Main Authors: Kadri, Yasmine, Phan, Michelle, Bambace, Nadia, Bernard, Léa, Cohen, Sandra, Delisle, Jean-Sébastien, Kiss, Thomas, Lachance, Sylvie, Roy, Denis-Claude, Sauvageau, Guy, Veilleux, Olivier, Roy, Jean, Ahmad, Imran
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.08.2022; MDPI
• Subjects: acute myeloid leukemia; allogenic hematopoietic cell transplantation; Analysis; Canada; Cancer; donor age; graft-versus-host disease; Health aspects; Hematopoietic stem cells; Mortality; myelodysplastic syndrome; non-relapse mortality; Oncology, Experimental; Transplantation; Canada
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol29080470

The purpose of this retrospective study was to study the correlation between donor age (DA) and non-relapse mortality (NRM) and relapse incidence (RI) among patients treated with allogeneic hematopoietic cell transplantation (aHCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in a single Canadian center. Data from 125 consecutive patients transplanted with a matched related or unrelated donor between 2015 and 2020 were analyzed using multivariable models. After a median follow-up of 2.8 years, the cumulative incidences of NRM and relapse were 19% and 35% at 5 years. Despite being independently associated with NRM and relapse-free survival (RFS), DA was not associated with RI. The independent determinants of NRM in addition to DA were patient age and hematopoietic cell transplantation comorbidity index (HCT-CI), independently of donor kinship. The effect of DA on NRM was found to be significantly increased over the age of 50 years. DA was not associated with incidence of acute graft-versus-host disease (aGVHD) but showed an association with the occurrence of chronic GVHD (cGVHD). In conclusion, younger donors should be favored to limit NRM and increase RFS in HLA-matched aHCT. The etiological mechanisms behind the association of DA with higher NRM remain to be elucidated.